

David Alan Schoenfeld

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8113809/publications.pdf>

Version: 2024-02-01

91
papers

7,505
citations

81743

39
h-index

60497

81
g-index

94
all docs

94
docs citations

94
times ranked

10134
citing authors

#	ARTICLE	IF	CITATIONS
1	Severe Cerebral Edema in Substance-Related Cardiac Arrest Patients. Resuscitation, 2022, , .	1.3	2
2	Impact of GH administration on skeletal endpoints in adults with overweight/obesity. European Journal of Endocrinology, 2022, 186, 619-629.	1.9	2
3	Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults. JAMA Network Open, 2022, 5, e222106.	2.8	34
4	Long-term survival of participants in the <sc>CENTAUR</sc> trial of sodium phenylbutyrate–taurursodiol in <sc>amyotrophic lateral sclerosis</sc>. Muscle and Nerve, 2021, 63, 31-39.	1.0	115
5	Enabling a learning healthcare system with automated computer protocols that produce replicable and personalized clinician actions. Journal of the American Medical Informatics Association: JAMIA, 2021, 28, 1330-1344.	2.2	22
6	Predictors and moderators of symptom change during cognitive-behavioral therapy or supportive psychotherapy for body dysmorphic disorder. Journal of Affective Disorders, 2021, 287, 34-40.	2.0	13
7	Sequential Therapy With Recombinant Human IGF-1 Followed by Risedronate Increases Spine Bone Mineral Density in Women With Anorexia Nervosa: A Randomized, Placebo-Controlled Trial. Journal of Bone and Mineral Research, 2021, 36, 2116-2126.	3.1	9
8	Estimation for an accelerated failure time model with intermediate states as auxiliary information. Lifetime Data Analysis, 2020, 26, 1-20.	0.4	4
9	Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence. Journal of Psychopharmacology, 2020, 34, 197-210.	2.0	10
10	Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis. New England Journal of Medicine, 2020, 383, 919-930.	13.9	299
11	Effect of Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients With COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 2165.	3.8	352
12	Prospective Assessment of the Feasibility of a Trial of Low Tidal Volume Ventilation for Patients with Acute Respiratory Failure. Annals of the American Thoracic Society, 2019, 16, 356-362.	1.5	20
13	Design and analysis of a clinical trial using previous trials as historical control. Clinical Trials, 2019, 16, 531-538.	0.7	11
14	S54. INTEGRATED DIABETES MANAGEMENT FOR INDIVIDUALS WITH SERIOUS MENTAL ILLNESS (SMI). Schizophrenia Bulletin, 2019, 45, S327-S327.	2.3	0
15	A Randomized Placebo-Controlled Trial of Low-Dose Testosterone Therapy in Women With Anorexia Nervosa. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 4347-4355.	1.8	14
16	Editorial: We may need large trials to find treatments for neurodegenerative diseases. Clinical Trials, 2019, 16, 120-121.	0.7	0
17	Reappraisal of Ventilator-Free Days in Critical Care Research. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 828-836.	2.5	210
18	A commentary on: statistical inference problems in sequential parallel comparison designs. Journal of Biopharmaceutical Statistics, 2019, 29, 1130-1133.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Efficacy and Posttreatment Effects of Therapist-Delivered Cognitive Behavioral Therapy vs Supportive Psychotherapy for Adults With Body Dysmorphic Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 363.	6.0	64
20	A pilot trial of RNS60 in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2019, 59, 303-308.	1.0	29
21	Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive <i>SOD1</i> ALS. <i>Neurology</i> , 2018, 90, e565-e574.	1.5	99
22	An open label study of a novel immunosuppression intervention for the treatment of amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 242-249.	1.1	35
23	Urate levels predict survival in amyotrophic lateral sclerosis: Analysis of the expanded Pooled Resource Open-Access ALS clinical trials database. <i>Muscle and Nerve</i> , 2018, 57, 430-434.	1.0	39
24	A randomized controlled trial of resistance and endurance exercise in amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2018, 19, 250-258.	1.1	44
25	Informatively clustering longitudinal microarrays using binary or survival outcome data. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2018, 4, 18-27.	0.3	0
26	Enhanced Bulbar Function in Amyotrophic Lateral Sclerosis: The Nuedexta Treatment Trial. <i>Neurotherapeutics</i> , 2017, 14, 762-772.	2.1	73
27	Comment on: Progression-Free Survival as a Surrogate for Overall Survival in Clinical Trials of Targeted Therapy in Advanced Solid Tumors. <i>Drugs</i> , 2017, 77, 1137-1138.	4.9	1
28	Predictors of tobacco abstinence in outpatient smokers with schizophrenia or bipolar disorder treated with varenicline and cognitive behavioral smoking cessation therapy. <i>Addictive Behaviors</i> , 2017, 71, 89-95.	1.7	11
29	Causal inference methods to study gastric tube use in amyotrophic lateral sclerosis. <i>Neurology</i> , 2017, 89, 1483-1489.	1.5	18
30	Relationship between Race and the Effect of Fluids on Long-term Mortality after Acute Respiratory Distress Syndrome. Secondary Analysis of the National Heart, Lung, and Blood Institute Fluid and Catheter Treatment Trial. <i>Annals of the American Thoracic Society</i> , 2017, 14, 1443-1449.	1.5	13
31	Power Calculations to Select Instruments for Clinical Trial Secondary Endpoints. A Case Study of Instrument Selection for Post-Traumatic Stress Symptoms in Subjects with Acute Respiratory Distress Syndrome. <i>Annals of the American Thoracic Society</i> , 2017, 14, 110-117.	1.5	6
32	Functional Decline is Associated with Hopelessness in Amyotrophic Lateral Sclerosis (ALS). <i>Journal of Neurology & Neurophysiology</i> , 2017, 08, .	0.1	17
33	Longitudinal immunological characterization of the first presensitized recipient of a face transplant. <i>JCI Insight</i> , 2017, 2, .	2.3	18
34	Remote video auditing with real-time feedback in an academic surgical suite improves safety and efficiency metrics: a cluster randomised study. <i>BMJ Quality and Safety</i> , 2016, 25, 947-953.	1.8	30
35	Coronary CT Angiography Versus Standard Emergency Department Evaluation for Acute Chest Pain and Diabetic Patients: Is There Benefit With Early Coronary CT Angiography?. <i>Journal of the American Heart Association</i> , 2016, 5, e003137.	1.6	20
36	Reply to Phillips, Morris, and Walker. <i>Clinical Infectious Diseases</i> , 2016, 62, 815-816.	2.9	5

#	ARTICLE	IF	CITATIONS
37	Quantitative strength testing in ALS clinical trials. <i>Neurology</i> , 2016, 87, 617-624.	1.5	37
38	Assessing survival benefit when treatment delays disease progression. <i>Clinical Trials</i> , 2016, 13, 352-357.	0.7	5
39	A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. <i>Nature Nanotechnology</i> , 2016, 11, 378-387.	15.6	201
40	Nonlinear Imputation of Pao2/Fio2 From Spo2/Fio2 Among Patients With Acute Respiratory Distress Syndrome. <i>Chest</i> , 2016, 150, 307-313.	0.4	127
41	How common are ALS plateaus and reversals?. <i>Neurology</i> , 2016, 86, 808-812.	1.5	78
42	Induced regulatory T cells in allograft tolerance via transient mixed chimerism. <i>JCI Insight</i> , 2016, 1, .	2.3	40
43	Reply. <i>Muscle and Nerve</i> , 2015, 52, 691-691.	1.0	2
44	Preâ€morbidity type 2 diabetes mellitus is not a prognostic factor in amyotrophic lateral sclerosis. <i>Muscle and Nerve</i> , 2015, 52, 339-343.	1.0	25
45	Prediction of Tumor Recurrence and Therapy Monitoring Using Ultrasound-Guided Photoacoustic Imaging. <i>Theranostics</i> , 2015, 5, 289-301.	4.6	154
46	Outcome-Driven Cluster Analysis with Application to Microarray Data. <i>PLoS ONE</i> , 2015, 10, e0141874.	1.1	6
47	Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression. <i>Nature Biotechnology</i> , 2015, 33, 51-57.	9.4	178
48	Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). <i>Clinical Infectious Diseases</i> , 2015, 61, 800-806.	2.9	206
49	Sensitive troponin assays in patients with suspected acute coronary syndrome: Results from the multicenter rule out myocardial infarction using computer assisted tomography II trial. <i>American Heart Journal</i> , 2015, 169, 572-578.e1.	1.2	23
50	Use of Coronary Artery Calcium Scanning Beyond Coronary Computed Tomographic Angiography in the Emergency Department Evaluation for Acute Chest Pain. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, .	1.3	44
51	The PRO-ACT database. <i>Neurology</i> , 2014, 83, 1719-1725.	1.5	222
52	Preventing ARDS. <i>Chest</i> , 2014, 146, 1102-1113.	0.4	47
53	Photosensitizer fluorescence and singlet oxygen luminescence as dosimetric predictors of topical 5-aminolevulinic acid photodynamic therapy nduced clinical erythema. <i>Journal of Biomedical Optics</i> , 2014, 19, 028001.	1.4	46
54	A novel application of the <i>Intent to Attend</i> assessment to reduce bias due to missing data in a randomized controlled clinical trial. <i>Clinical Trials</i> , 2014, 11, 494-502.	0.7	9

#	ARTICLE	IF	CITATIONS
55	Effect of adjunctive benzodiazepines on clinical outcomes in lithium- or quetiapine-treated outpatients with bipolar I or II disorder: Results from the Bipolar CHOICE trial. <i>Journal of Affective Disorders</i> , 2014, 161, 30-35.	2.0	18
56	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 1083-1091.	4.9	187
57	Clinicopathologic features associated with relapse in cryptogenic organizing pneumonia. <i>Human Pathology</i> , 2014, 45, 342-351.	1.1	47
58	A test for the relationship between a time-varying marker and both recovery and progression with missing data. <i>Statistics in Medicine</i> , 2011, 30, 718-724.	0.8	3
59	Bayesian design using adult data to augment pediatric trials. <i>Clinical Trials</i> , 2009, 6, 297-304.	0.7	61
60	The natural history of ALS is changing: Improved survival. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 324-331.	2.3	66
61	Design of phase II ALS clinical trials. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2008, 9, 16-23.	2.3	34
62	Trial of celecoxib in amyotrophic lateral sclerosis. <i>Annals of Neurology</i> , 2006, 60, 22-31.	2.8	276
63	Calculating the power or sample size for the logistic and proportional hazards models. <i>Journal of Statistical Computation and Simulation</i> , 2005, 75, 771-785.	0.7	22
64	Survival methods, including those using competing risk analysis, are not appropriate for intensive care unit outcome studies. <i>Critical Care</i> , 2005, 10, 103.	2.5	52
65	Pro/con clinical debate: It is acceptable to stop large multicentre randomized controlled trials at interim analysis for futility. Pro: Futility stopping can speed up the development of effective treatments. <i>Critical Care</i> , 2004, 9, 34.	2.5	26
66	Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome. <i>Critical Care Medicine</i> , 2002, 30, 1772-1777.	0.4	462
67	Metabolism of Orally Administered Androstenedione in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 3654-3658.	1.8	36
68	Hypogonadism in patients with acromegaly: data from the multi-centre acromegaly registry pilot study. <i>Clinical Endocrinology</i> , 2001, 54, 183-188.	1.2	76
69	Low bone mineral density in hormone-naïve men with prostate carcinoma. <i>Cancer</i> , 2001, 91, 2238-2245.	2.0	130
70	Nonparametric Estimation in a Cure Model with Random Cure Times. <i>Biometrics</i> , 2001, 57, 282-286.	0.8	37
71	A Simple Algorithm for Designing Group Sequential Clinical Trials. <i>Biometrics</i> , 2001, 57, 972-974.	0.8	17
72	Efficacy of Low Tidal Volume Ventilation in Patients with Different Clinical Risk Factors for Acute Lung Injury and the Acute Respiratory Distress Syndrome. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 231-236.	2.5	281

#	ARTICLE	IF	CITATIONS
73	Low bone mineral density in hormone-naïve men with prostate carcinoma. , 2001, 91, 2238.		1
74	The selective muscarinic M1 agonist AF102B decreases levels of total A β in cerebrospinal fluid of patients with Alzheimer's disease. Annals of Neurology, 2000, 48, 913-918.	2.8	150
75	A model for markers and latent health status. Journal of the Royal Statistical Society Series B: Statistical Methodology, 2000, 62, 747-762.	1.1	40
76	Withdrawal of Long-Term Physiological Growth Hormone (GH) Administration: Differential Effects on Bone Density and Body Composition in Men with Adult-Onset GH Deficiency*. Journal of Clinical Endocrinology and Metabolism, 2000, 85, 970-976.	1.8	92
77	Combining mortality and longitudinal measures in clinical trials. , 1999, 18, 1341-1354.		225
78	Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome. Antiviral Therapy, 1998, 3, 25-32.	0.6	15
79	Determinants of Abnormal Gonadotropin Secretion in Clinically Defined Women with Polycystic Ovary Syndrome1. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 2248-2256.	1.8	355
80	A Random-Effects Model for Multiple Characteristics with Possibly Missing Data. Journal of the American Statistical Association, 1997, 92, 775-779.	1.8	131
81	ANALYSIS OF MULTIPLE FAILURE TIME DATA FROM AN AIDS CLINICAL TRIAL. Statistics in Medicine, 1997, 16, 951-961.	0.8	17
82	LONG-TERM FOLLOW-UP IN AIDS CLINICAL TRIALS. , 1996, 15, 2359-2366.		1
83	Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat. Journal of Bone and Mineral Research, 1996, 11, 430-439.	3.1	43
84	Suppression by the sumatriptan analogue, CPâ€12,288 of câ€fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. British Journal of Pharmacology, 1995, 114, 987-992.	2.7	32
85	Analysing survival in the presence of an auxiliary variable. Statistics in Medicine, 1994, 13, 1747-1754.	0.8	51
86	Subsets of Glioblastoma Multiforme Defined by Molecular Genetic Analysis. Brain Pathology, 1993, 3, 19-26.	2.1	597
87	Design Considerations for AIDS Trials. New England Journal of Medicine, 1990, 323, 1343-1348.	13.9	149
88	Confidence Bounds for Normal Means under Order Restrictions, with Application to Dose-Response Curves, Toxicology Experiments, and Low-Dose Extrapolation. Journal of the American Statistical Association, 1986, 81, 186-195.	1.8	42
89	The asymptotic properties of nonparametric tests for comparing survival distributions. Biometrika, 1981, 68, 316-319.	1.3	436
90	Confidence Bounds for Normal Means under Order Restrictions, with Application to Dose-Response Curves, Toxicology Experiments, and Low-Dose Extrapolation. , 0, .		5

#	ARTICLE	IF	CITATIONS
91	A Random-Effects Model for Multiple Characteristics with Possibly Missing Data. , 0, .		25